← Back to news

Markets

Oppenheimer Raises Price Target on Broadcom (AVGO) to $325, Maintains Outperform

Y

Analysts Maintain Confidence on Mastercard (MA) as Digital Payment Growth Fuels Momentum

Y

Alphabet (GOOGL) Deepens U.S. AI/Cloud Footprint with Virginia Expansion

Y

Piper Sandler Lifts PT on Amgen (AMGN) to $342 From $328, Keeps an Overweight Rating

Y

Bank of America Securities Reiterates a Hold Rating on PDD Holdings (PDD)

Y

BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY)

Y

Jefferies Reiterates a Buy Rating on CVS Health (CVS) With a PT of $80

Y

Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission

Y

UBS Raises PT on ConocoPhillips (COP) to $123 From $116

Y

Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine

Y

Bank of America Securities Remains Bullish on AT&T Inc. (T)

Y

What Do Analysts Think About Verizon Communications (VZ)?

Y

What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)?

Y

H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44

Y

Citizens JMP Reiterates a Buy on Wix.com (WIX)

Y

Canaccord Genuity Reiterates a Buy Rating on Strategy Inc. (MSTR) With a $464 PT

Y

Jefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS)

Y

Stifel Nicolaus Maintains a Buy on Hubspot (HUBS), Sets a $650 PT

Y

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

Y

BofA Lowers PT on Nutanix (NTNX) to $93 From $95, Keeps a Buy Rating

Y

Argus Initiates Coverage of DexCom (DXCM) with a Buy Rating

Y

Wells Fargo Maintains a Hold on monday.com (MNDY)

Y

Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial

Y

China August PMI Edges Up to 49.4 From 49.3 in July

Y

Mortgage Refinancing Starts to Thaw as Rates Trend Down

Y